drugset / Trial / NCT04762355

Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

NCT04762355 ↗

Phase 1 Completed 48 enrolled Ipsen Ipsen · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.

Timeline

Start
2018-08-30
Primary completion
2019-01-03
Completion
2019-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Palovarotene Small molecule — Other

Indications